Search Results 941-950 of 16362 for monoclonal antibody

1. A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma - Mayo Clinic

   Monoclonal antibodies within 28 days; Corticosteroid administration >20 mg/day of prednisone or equivalent within 14 days; Proteasome inhibitors within 14 ...

2. Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis - Mayo Clinic

   Secondary or familial amyloidosis; · Life expectancy of < 3 months; · Symptomatic multiple myeloma; · Hypersensitivities to other monoclonal antibodies; · Known HIV ...

3. International Group Publishes Updated Criteria for Diagnosing Multiple Myeloma

   Rajkumar said multiple myeloma is always preceded sequentially by two asymptomatic conditions, monoclonal gammopathy of undetermined significance (MGUS) and ...

4. Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) - Mayo Clinic

   Prior monoclonal antibody within 4 weeks prior to study Day 1 (2 weeks for RS participants) or who has not recovered (i.e. ≤ Grade 1 or at baseline) from ...

5. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   ... monoclonal antibodies, and not a candidate for ... antibody syndrome. Patients receiving dual ... antibody positive, confirmed by HCV ribonucleic acid).

6. Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy - Mayo Clinic

   ... antibody at any point prior to registration -CD20-targeted monoclonal antibody (e.g., rituximab, obinutuzumab or biosimilars) =< 4 weeks prior to ...

7. Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma - Mayo Clinic

   Monoclonal antibodies: at least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody; Radiation therapy (RT): >= 2 weeks ...

8. A Study to Assess the Effectiveness, Safety and Tolerability of Lu AF82422 in Patients with Multiple System Atrophy - Mayo Clinic

   - The participant has been treated with an anti-?-synuclein monoclonal antibody, mesenchymal stem cells or an inhibitor of ?-synuclein aggregation within ...

9. Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer - Mayo Clinic

   ... monoclonal antibodies, other investigational agent) < 28 days prior to the first dose of study drug. Current or prior use of immunosuppressive medication ...

10. A Study of Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer - Mayo Clinic

    At least 28 days since last dose of chemotherapy prior to registration. Monoclonal antibody(ies). At least 28 days since last dose of monoclonal antibody prior ...